Our products
Triple receptor agonist
Retatrutide
A peptide designed to activate GLP-1, GIP and glucagon receptors, investigated in metabolic research.
How it works
It engages three hormone-receptor pathways involved in glucose regulation, appetite signalling and energy metabolism. This triple-receptor activity distinguishes it from single- and dual-receptor agonists.
Research context
Retatrutide has been investigated in human clinical trials for obesity and related metabolic conditions. Clinical-trial results concern controlled pharmaceutical preparations, not Omega Labs research material.